# Glutide for Ending Methamphetamine

> **NCT07204249** · PHASE2 · NOT_YET_RECRUITING · sponsor: **San Francisco Department of Public Health** · enrollment: 162 (estimated)

## Conditions studied

- Methamphetamine-dependence

## Interventions

- **DRUG:** Semaglutide
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07204249
- **Lead sponsor:** San Francisco Department of Public Health
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-01-15
- **Primary completion:** 2030-02-15
- **Final completion:** 2030-02-15
- **Target enrollment:** 162 (ESTIMATED)
- **Last updated:** 2025-10-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07204249

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07204249, "Glutide for Ending Methamphetamine". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT07204249. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*